Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with a lung tumor that is 5 cm or smaller and located in a central part of the lung, meaning the tumor is near major airways, large blood vessels, the food pipe (esophagus), or the heart (confirm exact location details with trial site)
- People with more than one lung tumor at the same time may also be considered, as long as at least one tumor meets the size and location requirements above
- People who are generally well enough to carry out daily activities with little or no assistance (rated on a standard medical scale as 0, 1, or 2 out of 4)
- People aged 18 or older
- People who are willing and able to sign a consent form for this study
Who may not be able to join:
- People who have previously had radiation treatment near the target tumor area, where earlier radiation reached certain high dose levels to nearby body structures such as the spinal cord, nerve bundles in the shoulder area (brachial plexus), parts of the digestive tract, the brainstem, or a large portion of the lung (confirm specific dose thresholds with trial site)
- People who currently have an active infection in the body, lungs, or around the heart
- People who have a condition causing ongoing inflammation or significant scarring of the lung tissue
- People who are currently pregnant or breastfeeding
- People who have any other medical condition that, in the opinion of the trial doctor, would make participation unsafe or unsuitable
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Henry S. Park, MD, MPH, Yale University
Phone: 203-200-2100
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety of the stereotactic body radiotherapy regimen (SBRT); local control (LC) of 3-fraction stereotactic body radiotherapy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.